[Business Wire] – Pfizer Inc. announced today top-line results from two Phase 3 clinical trials of tofacitinib, a novel, oral Janus kinase inhibitor that is being investigated for the treatment of adults with moderate-to-severe chronic plaque psoriasis: OPT Compare and OPT Retreatment .
Read more on this.
Pfizer Inc. (PFE), valued at $187.65B, started the session at $28.25.
Looking at today’s trading action, the company’s one day range from $28.02 to $28.41 with a … [visit site to read more]
Similar posts:- Market Update on The Coca-Cola Company (NYSE:KO) – Broker Darlings of the Dow: Coca-Cola Ranks As a Top 15 Analyst Pick [at Forbes] – A study of analyst recommendations at the...
- Company Update: Pfizer Inc. (NYSE:PFE) – Pfizer Invites Public To View And Listen To Webcast Of October 29 Conference Call With Analysts [Business Wire] – Pfizer Inc. invites investors and the general...
- Pfizer Inc. (NYSE:PFE) – Pfizer names Adobe CEO Narayen as a director [AP] – Pfizer has named Adobe Systems Inc. President and...
